Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Last Updated on: 28 February, 2024|Author: Getaka | Social: X Twitter Profile

Fundamental Analysis of Indoco Remedies Ltd

About the Company - Indoco Remedies Ltd

Indoco Remedies Ltd. is a Public Limited Listed company incorporated on 23/08/1947 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L85190MH1947PLC005913 and registration number is 005913. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1539.72 Cr. and Equity Capital is Rs. 18.43 Cr. for the Year ended 31/03/2022.
PharmaceuticalsIndoco House, 166 CST Road, Mumbai Maharashtra
NamePosition Held
Mr. Suresh G KareChairman
Ms. Aditi PanandikarManaging Director
Mr. Sundeep V BambolkarJoint Managing Director
Dr. Anand NadkarniNon Executive Director
Mr. D M GavaskarIndependent Director
Mr. Rajiv P KakodkarIndependent Director
Dr.(Ms.) Vasudha V KamatIndependent Director
Mr. Abhijit Y GoreIndependent Director

Indoco Remedies Ltd. Share Price Update

Share PriceValue
Previous Day₹351.30

Basic Stock Data of Indoco Remedies Ltd

Market Cap 3,454 Cr.
Current Price 375
High / Low417/306
Stock P/E32.5
Book Value 116
Dividend Yield0.60 %
ROCE17.4 %
ROE14.8 %
Face Value 2.00

Data Source:

Indoco Remedies Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Operating Profit60558786738171886265617163
OPM %18%18%22%22%21%20%18%20%16%15%14%15%14%
Other Income021100100004-6
Profit before tax38346165516048673839344623
Tax %33%26%35%36%35%32%20%26%26%34%29%24%31%
Net Profit25254042334039502826243516
EPS in Rs2.752.714.304.523.584.394.195.403.052.802.653.811.77

Indoco Remedies Ltd Quarterly Chart

Indoco Remedies Ltd Profit & Loss

MonthJun 2006Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Operating Profit439312016617115713577123225328288260
OPM %18%15%16%19%17%15%13%8%11%18%21%17%14%
Other Income1212214562321-1
Profit before tax434972110999148-929132237193142
Tax %27%12%20%24%17%15%15%69%16%30%35%26%
Net Profit31435883827741-32493155142101
EPS in Rs3.564.646.298.998.898.364.47-0.312.6210.1016.8015.4411.03
Dividend Payout %23%24%22%18%18%19%22%-95%11%15%13%15%

Indoco Remedies Ltd Profit & Loss Yearly Chart

Indoco Remedies Ltd Growth

Compounded Sales Growth
10 Years:10%
5 Years:10%
3 Years:15%
Compounded Profit Growth
10 Years:13%
5 Years:29%
3 Years:81%
Stock Price CAGR
10 Years:12%
5 Years:17%
3 Years:9%
1 Year:4%
Return on Equity
10 Years:11%
5 Years:11%
3 Years:15%
Last Year:15%

Indoco Remedies Ltd Balance Sheet

MonthJun 2006Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital12181818181818181818181818
Other Liabilities76157180230224266281301330279325297374
Total Liabilities3116927298469411,1971,2381,2581,2721,3151,4861,6581,938
Fixed Assets139322325340374440489468590570555678762
Other Assets1613323604434966666136056316778098641,078
Total Assets3116927298469411,1971,2381,2581,2721,3151,4861,6581,938

Indoco Remedies Ltd Reserves and Borrowings Chart

Indoco Remedies Ltd Cash Flow

MonthJun 2006Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 3769991091128912313212382174179
Cash from Investing Activity -16-43-41-88-111-171-135-104-56-67-121-208
Cash from Financing Activity -25-24-59-20-2132-39-16-64-30-4423
Net Cash Flow-32-11-050-51123-148-7

Indoco Remedies Ltd Financial Efficiency Indicators

MonthJun 2006Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days1277469666974737469697077
Inventory Days127130148181174189203209230245248228
Days Payable147959514613716615719518311710786
Cash Conversion Cycle1071081221021059711988116197212219
Working Capital Days1167473788081776457107113119
ROCE %20%17%21%17%12%7%1%6%16%23%17%

Indoco Remedies Ltd Financial Efficiency Indicators Chart

Indoco Remedies Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
No. of Shareholders24,85221,50824,51834,74637,27937,86338,49838,07235,71334,73135,43136,588

Indoco Remedies Ltd Shareholding Pattern Chart

No. of Indoco Remedies Ltd Shareholders

Indoco Remedies Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Nippon India Small Cap Fund27445590.2387.22
ICICI Prudential Smallcap Fund20906881.1166.44
Nippon India Pharma Fund18349241.0558.31
Franklin India Smaller Companies Fund13627000.4543.31
DSP Healthcare Fund13123242.4341.71
HDFC Capital Builder Value Fund - Regular Plan6735890.3821.41
Quant Small Cap Fund6097930.219.38
Mahindra Manulife Flexi Cap Fund3369281.0510.71
Quant Healthcare Fund3202956.310.18
UTI Healthcare Fund2716981.138.63

Indoco Remedies Ltd ROCE Trend

Indoco Remedies Ltd EPS Trend

Indoco Remedies Ltd Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
Basic EPS (Rs.)15.4416.8010.102.62-0.32
Diluted EPS (Rs.)15.4216.8010.102.62-0.32
Cash EPS (Rs.)23.1025.3718.0310.307.45
Book Value[Excl.RevalReserv]/Share (Rs.)111.5898.1783.4573.7571.69
Book Value[Incl.RevalReserv]/Share (Rs.)111.5898.1783.4573.7571.69
Revenue From Operations / Share (Rs.)181.07167.20134.73120.08105.09
PBDIT / Share (Rs.)31.3035.7724.6813.638.98
PBIT / Share (Rs.)23.6427.2116.745.951.22
PBT / Share (Rs.)20.9225.6714.323.10-1.01
Net Profit / Share (Rs.)15.4416.8010.102.62-0.31
NP After MI And SOA / Share (Rs.)15.4416.8010.102.62-0.31
PBDIT Margin (%)17.2821.3918.3111.358.54
PBIT Margin (%)13.0516.2712.424.951.15
PBT Margin (%)11.5515.3510.632.58-0.96
Net Profit Margin (%)8.5210.047.492.17-0.29
NP After MI And SOA Margin (%)8.5210.047.492.17-0.29
Return on Networth / Equity (%)13.8317.1112.093.54-0.43
Return on Capital Employeed (%)17.6523.6216.986.741.38
Return On Assets (%)8.5710.417.071.89-0.23
Long Term Debt / Equity (X)
Total Debt / Equity (X)0.300.
Asset Turnover Ratio (%)
Current Ratio (X)1.901.821.531.231.21
Quick Ratio (X)
Inventory Turnover Ratio (X)1.291.441.361.341.27
Dividend Payout Ratio (NP) (%)14.578.920.0011.46-317.32
Dividend Payout Ratio (CP) (%)9.745.910.002.9113.42
Earning Retention Ratio (%)85.4391.080.0088.54417.32
Cash Earning Retention Ratio (%)90.2694.090.0097.0986.58
Interest Coverage Ratio (X)11.5223.3110.214.794.03
Interest Coverage Ratio (Post Tax) (X)6.6811.955.181.920.85
Enterprise Value (Cr.)3301.123694.362857.472094.152073.68
EV / Net Operating Revenue (X)1.982.402.301.892.14
EV / EBITDA (X)11.4511.2112.5716.6725.05
MarketCap / Net Operating Revenue (X)1.802.252.141.741.93
Retention Ratios (%)85.4291.070.0088.53417.32
Price / BV (X)2.923.843.462.842.83
Price / Net Operating Revenue (X)1.802.252.141.741.93

Indoco Remedies Ltd Profitability Ratios (%)

Indoco Remedies Ltd Liquidity Ratios

Indoco Remedies Ltd Liquidity Ratios (%)

Indoco Remedies Ltd Interest Coverage Ratios (%)

Indoco Remedies Ltd Valuation Ratios

Fair Value of Indoco Remedies Ltd Stock

Fair Value: ₹561.31

The stock is undervalued by 49.68% compared to the current price ₹375

*Investments are subject to market risks

Strength and Weakness of Indoco Remedies Ltd Stock

  1. The company has higher reserves (643.85 cr) compared to borrowings (227.54 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (263.92 cr) and profit (95.08 cr) over the years.
  1. The stock is trading at a high valuation with an average P/B ratio of 14.95 and average Dividend Yield of 9.57%.
  2. The stock has a low average ROCE of 13.08%, which may not be favorable.
  3. The stock has a high average Working Capital Days of 86.58, which may not be favorable.
  4. The stock has a high average Cash Conversion Cycle of 132.67, which may not be favorable.

About the Author

Author Avatar

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Indoco Remedies Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE